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Genome-sequencing studies indicate that all humans carry many genetic variants predicted to
cause loss of function (LoF) of protein-coding genes, suggesting unexpected redundancy in the
human genome. Here we apply stringent filters to 2951 putative LoF variants obtained from
185 human genomes to determine their true prevalence and properties. We estimate that human
genomes typically contain ~100 genuine LoF variants with ~20 genes completely inactivated.
We identify rare and likely deleterious LoF alleles, including 26 known and 21 predicted severe
disease–causing variants, as well as common LoF variants in nonessential genes. We describe
functional and evolutionary differences between LoF-tolerant and recessive disease genes and a
method for using these differences to prioritize candidate genes found in clinical sequencing studies.
Genetic variants predicted to severely dis-rupt protein-coding genes, collectivelyknown as loss-of-function (LoF) variants,
are of considerable scientific and clinical interest.
Traditionally, such variants have been regarded
as rare and having a high probability of being
deleterious, on the basis of their well-established
causal roles in severe Mendelian diseases such as
cystic fibrosis and Duchenne muscular dystro-
phy. However, recent studies examining the com-
plete genomes of apparently healthy subjects have
suggested that such individuals carry at least 200
(1, 2) and perhaps as many as 800 (3) predicted
LoF variants. These numbers imply a previously
unappreciated robustness of the human genome
to gene-disrupting mutations and have important
implications for the clinical interpretation of hu-
man genome–sequencing data.
Comparison of reported LoF variants between
published genomes is complicated by differences
in sequencing technology, variant-calling algo-
rithms, and gene annotation sets between studies
(4, 5), and by the expectation that LoF variants
will be highly enriched for false positives. The
basis for this predicted enrichment is that strong
negative natural selection is expected to act against
the majority of variants inactivating protein-
coding genes, thereby reducing the amount of
true variation at these sites relative to the genome
average, whereas sequencing error is expected to
be approximately uniformly distributed; as a re-
sult, highly functionally constrained sites should
show lower levels of observed polymorphism
and substantially higher false-positive rates (4).
To date, no large-scale attempt has been made to
validate the LoF variants reported in published
human genome sequences.
LoF variants found in healthy individuals will
fall into several overlapping categories: severe re-
cessive disease alleles in the heterozygous state;
alleles that are less deleterious but nonetheless
have an impact on phenotype and disease risk;
benign LoF variation in redundant genes; genuine
variants that do not seriously disrupt gene func-
tion; and, finally, a wide variety of sequencing
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and annotation artifacts. Distinguishing between
these categories will be crucial for the com-
plete functional interpretation of human genome
sequences.
Obtaining and filtering candidate LoF var-
iants. We identified 2951 candidate LoF variants
using whole-genome sequencing data from 185
individuals analyzed as part of the pilot phase of
the 1000 Genomes Project (2), as well as detailed
analysis of high-coverage whole-genome sequenc-
ing data from a single anonymous European in-
dividual (6). The individuals represented three
population groups: Yoruba individuals from Ibadan,
Nigeria (YRI); 60 individuals of Northern and
Western European origin from Utah (CEU); and
30 Chinese individuals from Beijing and 30
Japanese individuals from Tokyo who were an-
alyzed jointly (CHB+JPT).
We adopted a definition for LoF variants
expected to correlate with complete loss of func-
tion of the affected transcripts: stop codon–
introducing (nonsense) or splice site–disrupting
single-nucleotide variants (SNVs), insertion/deletion
(indel) variants predicted to disrupt a transcript’s
reading frame, or larger deletions removing either
the first exon or more than 50% of the protein-
coding sequence of the affected transcript. We
further subdivided these variants into “full” LoF
variants predicted to affect all known protein-
coding transcripts of the affected gene and “par-
tial” variants affecting only a fraction of known
coding transcripts. All annotation was performed
against the Gencode v3b annotation (7) with the
algorithm VAT (8).
We then subjected our candidate list to a se-
ries of stringent informatic and experimental val-
idation steps (9). Informatic filtering was based
on local sequence context (such as the presence
of highly repetitive sequence), gene annotation
(such as variants affecting noncanonical splice
sites or located close to the end of the affected
open reading frame), analysis of the effects of
nearby variants (such as neighboring SNVs al-
tering the predicted functional effect of the can-
didate LoF variant), and measures of sequence
read mapping and quality (fig. S1). Where pos-
sible, thresholds for filtering were derived from
the experimental validation experiments below.
We validated all candidate LoF SNVs and
indels that were not excluded by other filters and
for whichwe could design assays (n = 1877) with
experimental genotyping using three Illumina
genotyping arrays and 819 custom Sequenom
assays run, where possible, on all 185 samples
from the low- and high-coverage 1000 Genomes
pilot projects. Large deletions had previously
been subjected to extensive validation (10). All
LoF variants identified in NA12878 were as-
sessed by comparison with independent 454
sequencing and array-based data from the same
individual, as well as targeted capillary sequenc-
ing of variants in highly repetitive regions. Finally,
786 variants were reexamined by complete man-
ual reannotation of the 689 affected gene models
by experienced curators, using the HAVANA an-
notation pipeline (7), to identify annotation errors
and flag variants unlikely to profoundly affect
gene function. All 589 candidate LoF variants
identified in NA12878 were subjected to inde-
pendent genotype validation and complete gene
model reannotation.
As expected, the proportion of likely sequenc-
ing and annotation errors in the initial candidate
set was high, with overlapping sets of 25.0, 26.8,
and 11.1% examined LoF variants being ex-
cluded as representing likely sequencing or map-
ping errors, annotation or reference sequence
errors, and variants unlikely to cause genuine LoF,
respectively. Candidate LoF variants removed by
filtering tended to be more common than high-
confidence variants (Fig. 1A). False-positive rates
due to sequencing errors (Fig. 1B) were higher
for LoFvariants than formissense and synonymous
variants in the CHB+JPT and YRI populations
Table 1. Numbers of LoF variants before and after filtering. Total numbers of candidate LoF variants and average number of LoF sites per individual
(homozygous sites in parentheses) are shown for each LoF class. For large deletions, numbers represent total number of genes predicted to be inactivated.
Variant
type
Before filtering After filtering
Total
1000G low-coverage
average per individual NA12878 Total
1000G low-coverage
average per individual NA12878
CEU CHB+JPT YRI CEU CHB+JPT YRI
Stop 1111 85.7 (21.8) 113.4 (26.7) 109.1 (23.7) 115 (25) 565 26.2 (5.2) 27.4 (6.9) 37.2 (6.3) 23 (2)
Splice 658 80.5 (29.5) 98.1 (35.6) 89.0 (30.4) 95 (32) 267 11.2 (1.9) 13.2 (2.5) 13.7 (1.9) 12 (1)
Frameshift
indel
1040 217.8 (112.1) 225.5 (121.7) 247.2 (118.7) 348 (159) 337 38.2 (9.2) 36.2 (9.0) 44.0 (8.0) 38 (11)
Large
deletion
142 32.4 (12.2) 31.2 (11.8) 31.4 (9.7) 31 (5) 116 28.3 (6.2) 26.7 (5.9) 26.6 (5.5) 24 (4)
Total 2951 416.4 (175.6) 468.2 (195.8) 476.7 (316.0) 654 (286) 1285 103.9 (22.5) 103.5 (24.3) 121.5 (21.7) 97 (18)
Fig. 1. (A) Derived allele frequency distribution in the CEU population for raw and high-confidence
LoF variants, compared to missense and synonymous coding variants. (Inset) Distribution of the
proportion of SNVs in each class at low allele counts (1 to 5). (B) False-positive rates (based on
independent array genotyping) for LoF variants filtered for annotation artifacts and frequency-
matched missense and synonymous SNVs. (C) Distribution of frameshift indels along the coding
region of affected genes, before and after filtering.




































(P < 10−8 for all comparisons) and significantly
higher than for missense variants in CEU (P <
0.05). Because most variants in a given genome
are common, the comparatively high rate of an-
notation errors among high-frequency LoF variants
meant that filtering resulted in a large reduction in
LoF variants per individual (Table 1).
We identified several sources of false-positive
LoF annotation that will require careful consid-
eration in clinical sequencing projects. For instance,
the predicted functional effect of a nonsense or
frameshift variant can be altered by other nearby
variants on the same chromosome (table S1 and
fig. S2), and predicted splice-disrupting SNVs
and indels can be rescued by nearby alternative
splice sites (fig. S3). Both nonsense SNVs and
frameshift indels are enriched toward the 3′ end
of the affected gene, consistent with a greater tol-
erance to truncation close to the end of the cod-
ing sequence (Fig. 1C); putative LoF variants
identified in the last 5% of the coding region
were thus systematically removed from our high-
confidence set, with the single exception of a
known LoF indel in the NOD2 gene. There is
also a discernible peak close to the 5′ end of
genes, suggesting that some disrupted transcripts
are rescued by transcriptional reinitiation at an
alternative start codon (Fig. 1C).
Notably, 415 (32.3%) of our high-confidence
LoF variants are partial LoF variants, affecting
only a subset of the known transcripts from the
affected gene, meaning that functional protein
may still be produced. We chose not to discard
such cases, as it is currently impossible to assess
the relative functional importance of different
transcripts for most genes, and partial LoF mu-
tations have previously been shown to be causal
in Mendelian diseases (11).
In total, 43.5% (1285/2951) of our candidate
LoF variants survived filtering. The resulting cat-
alog of high-confidence LoF variants is not com-
plete: The 1000 Genomes pilot projects had low
power to detect extremely rare variants (2), and
we will not have detected certain classes of LoF
variants, such as large gene-disrupting duplica-
tions, noncoding variants that disrupt gene ex-
pression or splicing regulation, or coding variants
that destroy protein function without overtly
disrupting an open reading frame (such as mis-
sense SNVs or in-frame indels). Several known
LoF variant–containing genes such as ACTN3 (12)
and CASP12 (13) were labeled as “polymorphic
pseudogenes,” meaning that the reference ge-
nome contains nonfunctional allele of the gene,
whereas in other haplotypes the gene is function-
al (14); it is likely that we missed LoF variants in
other uncharacterized genes from this class.
Nonetheless, this catalog represents the larg-
est available set of high-confidence human vari-
ants predicted to disrupt protein-coding genes.
We note that the majority of the LoF variants iden-
tified here are novel: 70% of the high-confidence
LoF SNVs and indels were not present in dbSNP
before the 1000 Genomes pilot project.
The true number of LoF variants in an in-
dividual genome. Using the systematically cu-
rated list of variants from NA12878, we estimate
that this anonymous individual with European
ancestry carries 97 LoF variants, with 18 present
in a homozygous state (Table 1 and table S2).
These numbers, though still indicating an unex-
pected tolerance for gene inactivation in humans
and being considerably higher than those based
on genotyping known nonsense SNVs alone (15),
are substantially lower than most previously pub-
lished estimates based onwhole-genome sequenc-
ing [e.g., (2, 3, 16)] and provide a benchmark for
further studies of individual variation in func-
tional gene content. This analysis also provides
a robust estimate of different variant classes on
gene inactivation: for instance, we find that 39%
of genes inactivated in the NA12878 genome
are the result of frame-shifting indels, a potential-
ly serious concern given that indels are typically
undercalled using short-read sequencing approaches
(2). Over a quarter (28.7%) of the LoF SNVs and
indels in NA12878 affect only a subset of the
known transcripts from the affected genes, em-
phasizing the need to consider alternative splic-
ing in the annotation of functional effects.
Properties of LoF variants and affected genes.
LoFSNVs aremarkedly enriched for low-frequency
alleles compared to synonymous and missense
SNVs (Fig. 1A), suggesting that many LoF var-
iants are deleterious to human health and hence
are prevented from increasing in frequency by
purifying natural selection. The number of high-
confidence LoF variants per individual is 25%
higher in the YRI (Nigerian) sample than in the
three non-African populations (P = 5.0 × 10−21;
Table 1), suggesting a higher level of variation in
functional gene content in African individuals
consistent with their greater overall genetic diver-
sity. However, we caution that larger samples with
more homogeneous sequencing quality across
populations will be required to confirm this finding
and assess its likely functional impact.
We compared the properties of genes carrying
at least one high-confidence LoF variant with
those of other protein-coding genes. Genes con-
taining high-confidence LoF alleles are relatively
less evolutionarily conserved, showing a higher
ratio of protein-altering to silent substitutions in
coding regions between human and macaque
(P = 2.8 × 10−52) and less evolutionary conserva-
tion in their promoter regions (GERP score; P =
3.7 × 10−16). On average, they have more closely
related gene familymembers (paralogs) than other
genes (P = 0.0058) and show greater sequence
identity to paralogs (P = 0.0068), suggesting that
Fig. 2. (A) Estimated probability of haploinsufficiency (presence of disease
due to heterozygous loss of function), using a model trained with an inde-
pendent set of LoF deletions as well as a set of known haploinsufficient
genes. (B) Association of coding variants with complex disease risk. Ob-
served –log10(P) values for disease association in 17,000 individuals from
seven complex disease cohorts and a shared control group, following im-
putation of variants identified by the 1000 Genomes low-coverage pilot, are
plotted against the expected null distribution for all LoF variants and
frequency-matched missense and synonymous SNPs. (C) Allele-specific ex-
pression analysis of nonsense variants, using RNA sequencing data from 119
lymphocyte cell lines. Circles show the proportion of LoF-carrying reads
spanning each site across all heterozygous individuals. Variants predicted to
cause nonsense-mediated decay (NMD, red) and those predicted to escape
NMD (blue) are arbitrarily ordered by genome position within each class.
Blue and red dashed horizontal lines indicate mean values in each class.
Error bars, 95% confidence interval.




































in many cases their function may be partially re-
dundant and also increasing the possibility that
LoF variants may be gained or lost through the
process of gene conversion (17), as has recently
been reported for disease mutations (18). They
also have lower connectivity in both protein-
protein interaction (P = 6.8 × 10−6) and gene inter-
action (P= 4.2 × 10−19) networks, suggesting that
LoF-containing genes are generally less central
to key cellular pathways, although there are ca-
veats to this interpretation (9). LoF-containing
genes are strongly enriched for functional cate-
gories related to olfactory reception and depleted
for genes implicated in protein-binding, transcrip-
tional regulation, and anatomical development
(table S8).
We estimated the probability that heterozy-
gous inactivation of a given gene will be del-
eterious (a state known as haploinsufficiency)
using a combination of functional and evolution-
ary parameters (9, 19). Our filtering process dis-
proportionately removed candidate LoF variants
with a higher predicted probability of haploin-
sufficiency, P(HI), consistent with the majority of
putative LoF variants in highly functionally con-
strained genes being artifactual (Fig. 2A). High-
confidence LoF variants remaining after filtering
have significantly lower P(HI) than variants dis-
carded by our filters (P = 2.1 × 10−16) or known
haploinsufficient genes (P = 1.8 × 10−73).
We identified 365 genes with multiple can-
didate LoF variants. The majority of the genes
with three or more independent LoF variants were
found to represent systematic sequencing errors:
for instance, the CDC27 gene contained 10 sep-
arate candidate splice-disrupting variants, all of
which were found to represent mapping errors
due to an inactive gene copy absent from the hu-
man reference sequence. Most of these variants
were removed by filtering (table S3). Of the re-
maining genes, some likely represent genes drift-
ing toward inactivation in the population: for
instance, the VWDE gene contains four separate
high-confidence LoF variants, with 42.7% of the
sequenced 1000G samples carrying at least one
nonfunctional copy of this gene.
Effects of LoF variants on human phenotypes
and disease risk. The high-confidence LoF set
includes many known LoF variants reported to
have effects on human traits (table S4). We also
found a number of previously uncharacterized
LoF variants likely to have phenotypic effects.
For instance, we identified three separate LoF
variants in PKD1L3 and one in PKD2L1; the
protein products of these two genes form a pu-
tative sour taste receptor complex (20, 21), so
these variants may underlie variation in sour taste
sensitivity between humans.
Our high-confidence LoF set includes many
variants relevant to severe human disease. We
identified 26 known recessive disease-causing mu-
tations in our high-confidence LoF set, including
mutations associated with the severe early-onset
conditions Leber congenital amaurosis, harlequin
ichthyosis, osteogenesis imperfecta, and Tay-Sachs
disease (table S5). We also identified 21 strong
candidates for novel disease-causing mutations:
high-confidence LoF variants affecting all known
transcripts of genes in which other null mutations
have been convincingly associated with Men-
delian disease, including adult-onset muscular
dystrophy, Charcot-Marie-Tooth disease, and
mucolipidosis (table S6). With one exception (a
variant associated with transplant graft-versus-
host disease), no individuals were homozygous
for the putative disease-causing alleles.
Given the evidence for the presence of known
deleterious variants, we hypothesized that LoF
variants may also be enriched for association
with risk of common, complex diseases. We in-
vestigated this hypothesis by imputing genotypes
for 417 LoF SNVs and indels into a total of
13,241 patients representing seven complex dis-
eases such as Crohn’s disease and rheumatoid
arthritis, along with 2938 shared controls, who
had previously been subjected to genome-wide
single-nucleotide polymorphism (SNP) geno-
typing (22). We confirmed a previously known
frameshift indel in the NOD2 gene associated
with Crohn’s disease, with a genome-wide sig-
nificant imputed P value of 1.78 × 10−14 (two
orders of magnitude more significant than the
best tag SNP). However, no other LoF variants
achieved genome-wide significance, and there
was no overall excess of association signals in
LoF variants compared to other coding variants
(Fig. 2B). Because our catalog is expected to
contain most genuine LoF variants at greater than
5% frequency, this result suggests that common
gene-disrupting variants play a minor role in com-
plex disease predisposition.
One explanation for the paucity of common
LoF variants associated with complex disease
risk is purifying selection, which is expected to
prevent most severely deleterious alleles from
reaching high population frequencies; this is con-
sistent with the skew toward low frequencies
among high-confidence LoF variants (Fig. 1A).
In addition, genes containing homozygous LoF
variants have more gene family members (me-
dian 5 versus 3; P = 3.76 × 10−3) and are less
Fig. 3. (A) Distribution of selected evolutionary and functional parameters for recessive
disease genes (blue) and LoF-tolerant genes (red) compared to all protein-coding genes (gray).
Values are transformed to z scores to allow parameters to be plotted together. Boxes show
interquartile range with medians indicated with a vertical black line, and whiskers terminate at
themost extreme point less than 1.5 times the interquartile range from the box. For each pair of
P values, the top value refers to the recessive versus LoF-tolerant comparison and the bottom
value refers to the LoF-tolerant versus genome background comparison. Because many of the
parameters are left-skewed, the medians typically fall below zero. (B) P value distribution for
linear discriminant model (LDM) trained using LoF-tolerant and recessive disease genes, based
on human-macaque DN/DS ratio and PPI network proximity to known recessive disease genes.
(C) Receiver-operating characteristic (ROC) curve for LDM distinguishing between LoF-tolerant
and recessive disease genes, both when olfactory receptor genes (ORs) are included [solid line,
area under curve (AUC) = 0.831] and excluded (dashed line, AUC = 0.814). DN/DS, ratio of
missense to synonymous substitutions; CNC GERP, GERP score for conserved noncoding
elements within 50 kb of gene; PPI, protein-protein interaction.




































conserved between macaque and human (P =
1.87 × 10−4) than genes containing only hetero-
zygous LoF variants, suggesting greater redun-
dancy in genes affected by high-frequency loss of
function. Similarly small effects on complex dis-
ease risk have previously been noted for large,
common copy-number variations, another class
of variant with a high prior probability of func-
tional impact (23).
Genotype imputation and case-control asso-
ciation studies have low power to detect asso-
ciations for low-frequency variants, so further
experiments involving direct genotyping of LoF
variants in large disease cohorts will be required
to characterize the impact of rare LoF variation
on human complex disorders.
Effects of nonsense SNVs on gene expression.
We examined the impact of validated nonsense
SNVs on gene expression using RNA sequenc-
ing data generated from lymphoblastoid cell lines
of 119 samples from two populations (24, 25).
Comparison of the relative expression of the LoF
and functional alleleswithin experimentally geno-
typed heterozygous individuals (Fig. 2C and table
S7) revealed a statistically significant reduction in
expression from the LoF allele in 8/49 (16.3%) of
variants with sufficient sequencing depth to be as-
sayed. As expected, this reduction in expression is
most common for variants predicted to trigger
nonsense-mediated mRNA decay (NMD), a cel-
lular process that degrades premature stop codon–
containing transcripts: 7/28 (25.0%) of predicted
NMD-triggering variants show significant evidence
of decay, compared to 1/21 (4.8%) of predicted
NMD-evading variants, and the proportion of
reads mapping to the alternate allele was signif-
icantly lower for predicted NMD-triggering var-
iants (median 0.352 versus 0.481; P = 0.0023).
However, most predicted NMD-triggering variants
have no detectable effect on gene expression.
These results provide functional confirmation
of true loss of gene function for aminority of LoF
variants. In addition, they demonstrate that the
most widely used algorithm for NMD prediction
(26) is an imperfect indicator of the effects of
nonsense SNVs on RNA expression.
Natural selection on LoF variants. We ex-
plored whether LoF variants as a class showed
evidence of recent positive selection, as expected
under the “less is more” hypothesis of adaptive
gene loss proposed by Olson (27). We examined
the overlap between high-confidence LoF var-
iants and regions showing potential signatures of
positive selection using frequency spectrum and
haplotype length–based tests on 1000 Genomes
pilot data (2). In contrast to the “less is more”
hypothesis, LoF variants overlappedwith positive-
ly selected regions no more often than frequency-
matched synonymous SNVs. However, we have
identified 20 high-confidence LoF variants in
candidate regions for positive selection that war-
rant further analysis (table S10).
In some cases, selection for gene inactivation
may act through the accumulation of multiple
rare LoF variants rather than increased frequency
of a specific LoF allele.We identified one potential
example of this: In addition to a relatively common
nonsense SNVin theCD36 gene reported to be the
target of positive selection in African populations
(28), we identified two rare, novel splice-disrupting
SNVs in the same gene. All three of these variants
were specific to the Yoruban (YRI) population,
suggesting thatmultiple null alleles forCD36may
be accumulating in African populations under the
influence of selection.
Using LoF-tolerant genes to predict the prob-
ability of disease causation for novel variants.
Homozygous inactivation of a gene can have a
range of phenotypic effects: At one end of the spec-
trum are severe recessive disease genes, while at the
other end are genes that can be inactivated with-
out overt clinical impact, referred to here as LoF-
tolerant genes. Clinical sequencing projects seeking
to identify disease-causing mutations would bene-
fit from improved methods to distinguish where
along this spectrum each affected gene lies.
Genes homozygously inactivated in 1000 Ge-
nomes Project samples are likely to fall close to
the LoF-tolerant end of the spectrum. These genes
therefore represent a comparison group that can
be used to define the functional and evolutionary
characteristics that distinguish these genes from
severe recessive disease genes.
We examined the 253 genes containing
validated LoF variants that were found to be
homozygous in at least one individual. These
LoF-tolerant genes are significantly less conserved
and have fewer protein-protein interactions than
the genome average (Fig. 3A). They are also
enriched for functional categories related to che-
mosensation, largely explained by the enrichment
of olfactory receptor genes in this class (13.0%
versus 1.4% genome-wide), and depleted for
genes involved in embryonic development and
cellular metabolism (table S8).
We then identified parameters that could
be used to classify candidate genes along the
disease/LoF-tolerant spectrum. We first removed
olfactory receptors from the LoF-tolerant set, as
these genes could be easily excluded as candi-
dates for most severe Mendelian diseases, leav-
ing 213 LoF-tolerant genes to compare with 858
known recessive disease genes. These two gene
categories were found to display marked differ-
ences in a wide range of properties (Fig. 3A).
We developed a linear discriminant model
based on human-macaque conservation and prox-
imity to recessive disease genes in a protein-
protein interaction network to classify genes into
LoF-tolerant and recessive disease classes (Fig.
3, B and C). Although insufficient to definitively
discriminate between the two classes, this algo-
rithm could be used to prioritize candidates iden-
tified by sequencing recessive disease patients for
replication and functional follow-up. We have
calculated a recessive disease probability score
for each protein-coding gene in the genome for
use in such analyses (9).
Conclusions. Here we describe a stringently
filtered catalog of variants disrupting the reading
frame of human protein-coding genes, including
the majority of such variants present at a pop-
ulation frequency of 1% or greater. Because large
numbers of candidate LoF variants are present in
the genomes of all individuals, but are highly
enriched for a variety of sequencing and anno-
tation errors, there is a need for caution in assign-
ing disease-causing status to novel gene-disrupting
variants found in patients. More reliable refer-
ence gene sets will help: Reference sequence and
automated gene annotation errors accounted for
44.9% of candidate LoF variants in our deeply
characterized individual genome, but most of
these have now been corrected as a result of this
project and other manual annotation efforts.
Our stringent filtering of the LoF variants
found in a single high-quality human genome
suggests that a typical “healthy” genome contains
~100 genuine LoF variants, with most of them
carried in the heterozygous state. Given that hu-
mans (29) and other species (30) have been es-
timated to carry fewer than five recessive lethal
alleles per genome, it seems likely that the ma-
jority of LoF variants found in an individual ge-
nome are common variants in nonessential genes,
although these may still have an effect on human
phenotypic variation. Nonetheless, the signature of
strong purifying selection against high-confidence
LoF variants as a class, and the discovery of nu-
merous known and predicted severe recessive dis-
ease alleles, indicates that many LoF alleles with
large effects on human fitness exist at low fre-
quency in the human population. Large sequenc-
ing and genotyping projects will be required to
uncover the full spectrum of these variants and
their effects on human disease risk.
We have found that LoF-tolerant and reces-
sive disease genes have differing functional and
evolutionary properties, allowing us to develop a
potential approach for prioritizing novel candi-
date recessive disease variants identified in pa-
tient samples for functional follow-up. As further
examples of LoF-tolerant genes are obtained from
high-throughput sequencing studies, the power of
this type of classification approach is likely to
grow considerably.
Finally, we note that our catalog of validated
LoF variants comprises a list of naturally oc-
curring “knockout” alleles for more than 1000
human protein-coding genes, many of which cur-
rently have little or no functional annotation at-
tached to them. Identification and systematic
phenotyping of individuals homozygous for these
variants could provide valuable insight into the
function of many poorly characterized human
genes.
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Unraveling the Spin Polarization of the
n = 5/2 Fractional Quantum Hall State
L. Tiemann,1,2* G. Gamez,1 N. Kumada,1 K. Muraki1,2*
The fractional quantum Hall (FQH) effect at filling factor n = 5/2 has recently come under close
scrutiny, as its ground state may possess quasi-particle excitations obeying nonabelian statistics,
a property sought for topologically protected quantum operations. However, its microscopic origin
remains unknown, and candidate model wave functions include those with undesirable abelian
statistics. We report direct measurements of the electron spin polarization of the n = 5/2 FQH state
using resistively detected nuclear magnetic resonance. We find the system to be fully polarized,
which unambiguously rules out the most likely abelian contender and lends strong support for
the n = 5/2 state being nonabelian. Our measurements reveal an intrinsically different nature
of interaction in the first excited Landau level underlying the physics at n = 5/2.
Whenahighly correlated two-dimensionalelectron system (2DES) is placed un-der a strong perpendicular magnetic
field B at low temperature, the interplay between
quantum mechanics and the interelectron inter-
action produces spectacular effects. When the
filling factor n, the ratio between the number of
electrons (ns) and the number of magnetic flux
quanta [nf = (e/h)B; e: electron charge; h: Planck’s
constant], takes particular “magic” rational val-
ues p/q (p, q: integer), an energy gap forms based
purely on electron correlation and makes the sys-
tem’s transverse (Hall) resistance invariant to small
perturbations (1). In these fractional quantum
Hall (FQH) phases, small variations of ns or nf
generate quasiparticles with a fractional charge
e* = Te/q (2). The composite-fermion (CF) mod-
el (3), in which an electron is transformed into a
fictitious particle by merging it with an even num-
ber of flux quanta, explains FQH effects for odd
values of q. The most notable FQH state with an
even denominator observed to date, the n = 5/2
FQH state (4), cannot be described within this
simple CF picture, and it has recently come under
close scrutiny as it may support something even
more tantalizing: a nonabelian state of matter (5–7).
Charge excitations from this potential nonabelian
state would be carried by quasiparticles whose in-
terchange takes the system from one of its many
ground states to another, whereas the interchange
of ordinary abelian quasiparticles only adds a phase
to their wave functions. This unusual property,
specific to nonabelian states, is proposed as the
foundation for topological quantum computation
that would be robust against environmental deco-
herence (8). Both nonabelian (5, 9, 10) and abe-
lian (11) states have been proposed for n = 5/2,
but experimental efforts (12–16) have not dis-
criminated clearly between them. Twomost prob-
able wave function candidates that emerged through
quasiparticle tunneling experiments on n = 5/2
(13) are the nonabelian anti-Pfaffian state (9, 10)
and the abelian (331) state (11). One can dis-
criminate between them by measuring the spin po-
larization of the state (17–19), as the former is
fully polarized, and the latter unpolarized (18, 19).
We perform thismeasurement using a 100-mm-
wide Hall bar (Fig. 1A) with the 2DES confined
to a 27-nm-wide gallium arsenide (GaAs)
quantum well. A back gate enables us to tune
the electron density n from 0.5 × 1015 to 4.2 ×
1015 m−2. At n = 4.2 × 1015 m−2, the longitudinal
resistance Rxx and the Hall resistance Rxy show a
well-developed n = 5/2 FQH state at 12 mK,
along with pronounced FQH features at n = 7/3
and 8/3, indicating a high sample quality (20)
(Fig. 1B).
Our measurement of the spin polarization ex-
ploits the hyperfine interaction that intrinsically
exists between the magnetic moments of the atoms
constituting the GaAs quantumwell and the spins
of the electrons confined therein. When the 2DES
has a nonzero spin polarization P, nuclei in con-
tact with the 2DES experience a local magnetic
field, which shifts their nuclear resonance fre-
quency to a lower value by an amount propor-
tional to P (Knight shift Ks). We measure Ks
using the resistively detected nuclear magnetic
resonance (RD-NMR) technique (21), where the
resonant absorption of radio frequency (rf ) and
the resultant change in the nuclear polarization
1NTTBasicResearch Laboratories,NTTCorporation,3-1Morinosato-
Wakamiya, Atsugi 243-0198, Japan. 2ERATO Nuclear Spin
Electronics Project, Japan Science and Technology Agency
(JST), Kawaguchi 332-0012, Japan.
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www.sciencemag.org    sCiEnCE    erratum post date    20 apriL 2012 
Erratum
Research Articles: “A systematic survey of loss-of-function variants in human protein-
coding genes” by D. G. MacArthur et al. (17 February, p. 823). In Fig. 3C, the axis labels 
“False Positive Rate” and “True Positive Rate” should have been swapped. The corrected 
figure is shown here. The figure has been corrected in the HTML version online.
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individuals, the process of clinical sequencing needs to reassess how to identify likely causative alleles.
within an individual. Because many known disease-causing genes were identified in ''normal'' 
average person has about 100 true loss-of-function alleles of which approximately 20 have two copies
from the 1000 Genomes Project, as well as an additional European individual, and found that the 
) extensively validated the genomesQuintana-Murci (p. 823; see the Perspective by et al.MacArthur 
variants. In order to identify the true scope of loss-of-function genes within the human genome, 
of genome and exome sequencing, have often turned out to be sequencing errors rather than true genetic
genomes. However, putative loss-of-function genes, which are often some of the first identified targets 
Identifying genes that give rise to diseases is one of the major goals of sequencing human
Defective Gene Detective
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